Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Common Equity (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Common Equity for 4 consecutive years, with $258.4 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Common Equity rose 40.68% year-over-year to $258.4 million, compared with a TTM value of $258.4 million through Sep 2023, up 40.68%, and an annual FY2022 reading of $276.9 million, up 72.76% over the prior year.
  • Common Equity was $258.4 million for Q3 2023 at Terns Pharmaceuticals, down from $274.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $287.7 million in Q1 2023 and bottomed at -$119.8 million in Q3 2020.
  • Average Common Equity over 4 years is $121.6 million, with a median of $172.2 million recorded in 2021.
  • The sharpest move saw Common Equity skyrocketed 290.51% in 2021, then dropped 24.33% in 2022.
  • Year by year, Common Equity stood at -$117.4 million in 2020, then surged by 236.5% to $160.3 million in 2021, then surged by 72.76% to $276.9 million in 2022, then dropped by 6.69% to $258.4 million in 2023.
  • Business Quant data shows Common Equity for TERN at $258.4 million in Q3 2023, $274.2 million in Q2 2023, and $287.7 million in Q1 2023.